CC-96191 activated NK cells but not T cells; while maximum anti-AML efficacy was similar, soluble cytokine levels were 10- to >100-fold lower than with a protein drug that binds CD33 and CD3 on T cells. Here, CD33 is linked to acute myeloid leukemia.